In this context, the use of dendritic cells loaded with survivin-peptide (Clinical trial identifier NCT01456065) or survivin mRNA (Clinical trial identifier NCT01334047, NCT00978913) in association with telomerase and p53 mRNAs are being evaluated in clinical trials in patients with ovarian cancer, metastatic breast cancer and malignant melanoma. Here, BIRC5 is linked to melanoma.